Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMELLIA: Hu5F9-G4 in Haematological Malignancies
NCT02678338Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2015
- Primary completion
- Nov 2018
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of magrolimab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Gilead Sciences. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Nov 2015; status: completed.
02
Drugs
magrolimab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02678338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02678338.